Evidence map›Paper›PMID 24696488›Full record

ArticleJournal of virology2014

Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination.

Daniel Byrd, Nicole Shepherd, Jie Lan, Ningjie Hu, Tohti Amet, Kai Yang, Mona Desai, Qigui Yu

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Daniel ByrdDepartment of Microbiology and Immunology and Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Nicole ShepherdDepartment of Microbiology and Immunology and Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jie LanDepartment of Microbiology and Immunology and Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ningjie HuZhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, Wenzhou Medical College, University Park, Wenzhou, China.
Tohti AmetDepartment of Microbiology and Immunology and Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kai YangDepartment of Microbiology and Immunology and Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana, USA Zhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, Wenzhou Medical College, University Park, Wenzhou, China.
Mona DesaiDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Qigui YuDepartment of Microbiology and Immunology and Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana, USA Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA andyu@iupui.edu.
Indiana University School of MedicineWenzhou Medical University · CNIndiana University – Purdue University Indianapolis · US

Funding

Immunology and Infectious Diseases Training ProgramT32AI060519 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI MARK H KAPLAN · 2004 to 2026
$6.0M
Training in STIs and infections of global health significanceT32AI007637 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI WOOLS-KALOUSTIAN, KARA KAY · 2001 to 2020
$3.4M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015481 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FIFE, ROSE S · 2001 to 2001
$1.6M
Specific killing of latently HIV-1-infected cells after provirus reactivationR21AI104268 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI YU, QIGUI A. · 2013 to 2014
$429k
NCRR NIH HHS C06 RR015481NCRR NIH HHS C06 RR015481-01NIAID NIH HHS 1R21AI104268NIAID NIH HHS R21 AI104268NIAID NIH HHS T32 AI007637NIAID NIH HHS T32 AI060519
6 · The paper itself

Abstract

unlabelledHuman monocytic and professional antigen-presenting cells have been reported only to exhibit abortive infections with vaccinia virus (VACV). We found that monocyte-derived macrophages (MDMs), including granulocyte macrophage colony-stimulating factor (GM-CSF)-polarized M1 and macrophage colony-stimulating factor (M-CSF)-polarized M2, but not human AB serum-derived cells, were permissive to VACV replication. The titers of infectious virions in both cell-free supernatants and cellular lysates of infected M1 and M2 markedly increased in a time-dependent manner. The majority of virions produced in permissive MDMs were extracellular enveloped virions (EEV), a secreted form of VACV associated with long-range virus dissemination, and were mainly found in the culture supernatant. Infected MDMs formed VACV factories, actin tails, virion-associated branching structures, and cell linkages, indicating that MDMs are able to initiate de novo synthesis of viral DNA and promote virus release. VACV replication was sensitive to inhibitors against the Akt and Erk1/2 pathways that can be activated by VACV infection and M-CSF stimulation. Classical activation of MDMs by lipopolysaccharide (LPS) plus gamma interferon (IFN-γ) stimulation caused no effect on VACV replication, while alternative activation of MDMs by interleukin-10 (IL-10) or LPS-plus-IL-1β treatment significantly decreased VACV production. The IL-10-mediated suppression of VACV replication was largely due to Stat3 activation, as a Stat3 inhibitor restored virus production to levels observed without IL-10 stimulation. In conclusion, our data demonstrate that primary human macrophages are permissive to VACV replication. After infection, these cells produce EEV for long-range dissemination and also form structures associated with virions which may contribute to cell-cell spread. IMPORTANCE: Our results provide critical information to the burgeoning fields of cancer-killing (oncolytic) virus therapy with vaccinia virus (VACV). One type of macrophage (M2) is considered a common presence in tumors and is associated with poor prognosis. Our results demonstrate a preference for VACV replication in M2 macrophages and could assist in designing treatments and engineering poxviruses with special considerations for their effect on M2 macrophage-containing tumors. Additionally, this work highlights the importance of macrophages in the field of vaccine development using poxviruses as vectors. The understanding of the dynamics of poxvirus-infected foci is central in understanding the effectiveness of the immune response to poxvirus-mediated vaccine vectors. Monocytic cells have been found to be an important part of VACV skin lesions in mice in controlling the infection as well as mediating virus transport out of infected foci.

Indexed as

Virus ReplicationAnimalsCells, CulturedHumansInterleukin-1Interleukin-10MacrophagesMiceMonocytesVacciniaVaccinia virusInterleukin-1Interleukin-10

Identifiers

PMID24696488
PMCPMC4054380
OpenAlexW2042335926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.